Hemophilia Stories
- Will getting a blood transfusion change your DNA? Yes and no.
- Biogen Inc said on Tuesday it would spin off its hemophilia drug business as a publicly traded company in a tax-free transaction, leaving the drugmaker to focus on developing drugs for neurodegenerative diseases.
- Despite positive medical progress, many men living with hemophilia face treatment disparities and frequent bleeding.
- Baxalta Inc's drug, Adynovate, has been approved to control and reduce the frequency of bleeding episodes in patients with Hemophilia A, the agency said in a statement on Friday.
- A new virus has been found to be transmitted through blood transfusions, but it doesn't seem dangerous.
- Roche's experimental hemophilia drug will be fast-tracked after the Food and Drug Administration granted it breakthrough therapy status.
- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients.
- Pfizer Inc, the world's leading biopharmaceutical company, today announced that the results of a number of hemophilia studies will be presented at the World Federation of Hemophilia (WFH) 2010 Congress.